Asia Green Energy Public Company Limited (AGE.R)
SET 
AMEX Primary SET Summary
AGE.R Chart
Asia Green Energy Public Company Limited (AGE.R) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Asia Green Energy Public Company Limited ever had a stock split?
Asia Green Energy Public Company Limited Profile
| - Industry | - Sector | Dr. Joanne M. Hackett Ph.D. CEO | SET Exchange | US00848H1086 ISIN |
| United States Country | 4 Employees | - Last Dividend | 15 Mar 2024 Last Split | - IPO Date |
Overview
AgeX Therapeutics, Inc., a pioneering biotechnology firm with a focus on developing innovative therapies aimed at human aging and degenerative diseases, marked a significant milestone in its history as of March 26, 2024, when it was acquired by Serina Therapeutics, Inc., through a reverse merger transaction. Situated in Alameda, California, and founded in 2017, AgeX has been at the forefront of exploring the potential of novel therapeutics. Their ambitious scientific endeavors encompass a wide array of treatments designed to combat the complexities of aging and associated conditions, leveraging cutting-edge research and collaborative efforts, notably with the University of California at Irvine, to push the boundaries of cellular therapies targeting neurological disorders and diseases.
Products and Services
- AGEX-BAT1
A groundbreaking cell therapy product candidate, AGEX-BAT1 is in development to address a spectrum of age-related metabolic disorders, including Type II adult-onset diabetes and obesity. This innovative treatment encapsulates AgeX's commitment to combating the burdens of aging through therapeutic intervention.
- AGEX-VASC1
AGEX-VASC1 represents a cutting-edge cell-based therapeutic approach aimed at revitalizing vascular support in aged ischemic tissues. Target conditions include peripheral vascular disease and ischemic heart disease, with the therapy poised to offer new hope in restoring circulatory health and functionality.
- AGEX-iTR1547
In the realm of discovery, AGEX-iTR1547 stands out as a leader among small molecule drug-based therapeutic candidates, focusing on the ambitious goal of achieving scarless wound repair. This drug-based formulation embodies AgeX’s innovative strategy towards engaging the body’s healing processes with precision and efficiency.
- AGEX-iTR1550 (Renelon)
As AgeX's leading biologic candidate for induced tissue regeneration, AGEX-iTR1550 (Renelon) heralds a new era in gene delivery technology. This cutting-edge solution showcases the company's dedication to unlocking the regenerative potential of the human body, setting a new standard for therapeutic innovation in the process.
